PCSK9 inhibitors represent a new therapeutic option for statin intolerant individuals.

“

This perspective reviews the scope of statin associated adverse events, and the clinical consequences for patients who cannot tolerate statins. Validated tools and treatment algorithms for re-introducing statins at lower doses or less frequent dosing are the first steps in the approach to the statin intolerant patient. However, patients who cannot tolerate effective doses of statins remain at high cardiovascular risk. Several trials with PCSK9 inhibitors demonstrate that this class of agents is effective for lowering LDL cholesterol and represents an alternative or complimentary treatment option.

”